AC Immune SA (NASDAQ:ACIU) introduced that it’s going to obtain the second ReTain-related milestone cost of CHF 24.6 million below its settlement with Janssen Prescription drugs, a Johnson & Johnson firm. With final December’s milestone cost, this brings the overall milestone funds acquired for ACI-35.030 associated to this trial to CHF 40 million. Supply: Press Launch
Trending
- Honda, Nissan set to announce launch of integration talks, media experiences say By Reuters
- Everyone seems to be Eyeing XRP Features Whereas This Presale with Large Potential Is Beneath the Radar
- Pondering of gifting a down fee this vacation season? This is what it is best to know – Mortgage Charges & Mortgage Dealer Information in Canada
- A NEW APPROACH TO EXPERT ADVISOR OPTIMISATION
- Simply Listed | 8246 Man O Conflict Highway
- Sonic Chain Hits Main Block Milestone, Right here Are Essential Stats
- Odds now almost one in 5 the Fed does nothing subsequent yr (S&P Full Indices:SP500)
- States not in favour of bringing ATF below GST, says finance minister
AC Immune receives second milestone cost below Janssen settlement (NASDAQ:ACIU)
Company
Categories
Menu
Bitcoin (BTC)
$ 96,047.00
Ethereum (ETH)
$ 3,346.38
BNB (BNB)
$ 665.71
Solana (SOL)
$ 186.78
Copyright © 2024